ghafil, Z., Alkhalidi, N., Alabbassi, M. (2025). Efficacy and Tolerability of Levofloxacin versus Clarithromycin based First Line Triple Therapy for Eradication of Helicobacter pylori Infection: A Comparative Study. , 24(2), 212-217. doi: 10.52573/ipmj.2025.145526
zainab hamdan ghafil; Nawal Mehdi Alkhalidi; Mustafa Ghazi Alabbassi. "Efficacy and Tolerability of Levofloxacin versus Clarithromycin based First Line Triple Therapy for Eradication of Helicobacter pylori Infection: A Comparative Study". , 24, 2, 2025, 212-217. doi: 10.52573/ipmj.2025.145526
ghafil, Z., Alkhalidi, N., Alabbassi, M. (2025). 'Efficacy and Tolerability of Levofloxacin versus Clarithromycin based First Line Triple Therapy for Eradication of Helicobacter pylori Infection: A Comparative Study', , 24(2), pp. 212-217. doi: 10.52573/ipmj.2025.145526
ghafil, Z., Alkhalidi, N., Alabbassi, M. Efficacy and Tolerability of Levofloxacin versus Clarithromycin based First Line Triple Therapy for Eradication of Helicobacter pylori Infection: A Comparative Study. , 2025; 24(2): 212-217. doi: 10.52573/ipmj.2025.145526

Efficacy and Tolerability of Levofloxacin versus Clarithromycin based First Line Triple Therapy for Eradication of Helicobacter pylori Infection: A Comparative Study

Iraqi Postgraduate Medical Journal
Article 10, Volume 24, Issue 2, April 2025, Pages 212-217    PDF (215.83 K)
Document Type: Research Paper
DOI: 10.52573/ipmj.2025.145526
Authors
zainab hamdan ghafil* 1; Nawal Mehdi Alkhalidi2; Mustafa Ghazi Alabbassi3
1clinical pharmacist in the children welfare teaching hospital
2Gastroenterology & Hepatology Teaching Hospital, Medical City -,Ministry of Health and Environment, Baghdad, Iraq
3University of AL-Kafeel-College of Pharmacy, Iraq
Abstract
Abstract

Background: The increasing prevalence of antibiotic-resistant strains of Helicobacter pylori contributed to reduce the effectiveness of the first-line standard therapy. Consequently, it is necessary to identify alternative regimens that provide better or comparable efficacy and safety.

Objective: Compare the efficacy and tolerability of 10days levofloxacin-based triple therapy versus clarithromycin-based triple therapy as a first-line eradication regimen of Helicobacter pylori.

Patients and methods: This is an open label observational comparative study. A total of 100 patients with Helicobacter pylori infection were selected; 50 patients were taking 10 day levofloxacin-based triple therapy and the other 50 patients were on 14 day clarithromycin based triple therapy. Eradication rate and adverse effects were evaluated.

Results: Helicobacter pylori eradication rates were: levofloxacin group 74%, and clarithromycin group 54%. There were a statistically significant differences in the efficacy between the two regimens (p value < 0.05). In addition, no relevant differences in adverse effects were demonstrated. There were no significant relationship between Helicobacter pylori eradication and gender, age, or smoking.

Conclusion: This study showed that levofloxacin-based triple therapy is significantly more effective than clarithromycin-based therapy in the eradication of Helicobacter pylori infection but it does not reach the recommended eradication threshold.

Keywords: Antibiotic resistance, Clarithromycin, Eradication rate, Helicobacter pylori, Levofloxacin.
Keywords
Antibiotic resistance; Clarithromycin; Eradication rate; Helicobacter pylori; Levofloxacin
References
  1. Kaiyu Y, Yuqing L, Xuedong Z. Overview of researches for Helicobacter pylori in oral cavity and stomach. West China Journal of Stomatology. 2014;32. doi: 10.7518/hxkq.2014.03.025.
  2. Li Y, Choi H, Leung K, Jiang F, Graham DY, Leung WK. Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology. 2023;8:553-64.
  3. Tsay F-W, Hsu P-I. pylori infection and extra-gastroduodenal diseases. Journal of biomedical science. 2018;25:1-8. doi: 10.1186/s12929-018-0469-6.
  4. De Francesco V, Bellesia A, Ridola L, Manta R, Zullo A. First-line therapies for Helicobacter pylori eradication: a critical reappraisal of updated guidelines. Annals of Gastroenterology. 2017;30:373. doi: 10.20524/aog.2017.0166.
  5. Malfertheiner P, Megraud F, O'morain C, Gisbert J, Kuipers E, Axon A, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence consensus report. Gut. 2017;66:6-30. doi: 10.1136/gutjnl-2016-312288.
  6. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018;155:1372-82.
  7. Ho JJ, Navarro M, Sawyer K, Elfanagely Y, Moss SF. Helicobacter pylori antibiotic resistance in the United States between 2011 and 2021: a systematic review and meta-analysis. The American Journal of Gastroenterology. 2022;117:1221-30.
  8. Bujanda L, Nyssen OP, Vaira D, Saracino IM, Fiorini G, Lerang F, Georgopoulos S, Tepes B, Heluwaert F, Gasbarrini A, Rokkas T. Antibiotic resistance prevalence and trends in patients infected with Helicobacter pylori in the period 2013–2020: Results of the European Registry on H. pylori Management (Hp-EuReg). Antibiotics. 2021;10:1058.
  9. Kocazeybek B, Tokman HB. Prevalence of primary antimicrobial resistance of pylori in Turkey: a systematic review. Helicobacter. 2016;21:251-60. doi: 10.1111/hel.12272.
  10. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori American Journal of Gastroenterology. 2017;112:212-39. doi:10.1038/s41395-018-0132-6.
  11. Morcillo Muñoz J, Otero Regino W, Gómez Zuleta M. How can Helicobacter pylori eradication therapies be improved? Revista Colombiana de Gastroenterologia. 2018;33:437-47.
  12. Hussein N, Tunjel I, Majed H, Yousif S, Aswad S, Assafi M. Duodenal ulcer promoting gene 1(dupA1) is associated with A2147G clarithromycin-resistance mutation but not interleukin-8 secretion from gastric mucosa in Iraqi patients. New microbes and new infections. 2015;6:5-10. doi: 10.1016/j.nmni.2015.02.005.
  13. Majeed PD, KJ K. Seroprevalence of Helicobacter Pylori Infection among Patients with Gastroduodenal Disorders in Erbil City. Diyala Journal of Medicine. 2020;18:91-101. org/10.26505/DJM.18014880818.
  14. Al-Jubori SS, Al_Kademy IM, Ali MR, Ali ASM. Occurrence of Helicobacter pylori among Iraqi patients with suspected gastric ulcer: histopatological study for gastric mucosal biopsies. Advances in Environmental Biology. 2016;10:224-31.
  15. Hussein NR, Robinson K, Atherton JC. A study of age-specific Helicobacter pylori seropositivity rates in Iraq. Helicobacter. 2008;13:306-7. doi: 10.1111/j.1523-5378.2008.00618.
  16. Curado MP, de Oliveira MM, de Araújo Fagundes M. Prevalence of Helicobacter pylori infection in Latin America and the Caribbean populations: A systematic review and meta-analysis. Cancer epidemiology. 2019;60:141-8. doi: 10.1016/j.canep.2019.04.003.
  17. Elantouny NG, Abo Bakr AA, EL-Sokkary RH, Elshahat YE. Levofloxacin versus Clarithromycin-based Therapy for Eradication of Helicobacter Pylori Infection: A Comparative Study. Zagazig University Medical Journal. 2019;25:500-7. doi: 10.21608/zumj.2019.8141.10510.
  18. Cheha KM, Dib SOA, Alhalabi MM. Pilot study: comparing efficacy of 14-day triple therapy Clarithromycin versus levofloxacin on eradication of Helicobacter pylori infection in Syrian population single-center experience. Avicenna journal of medicine. 2018;8:14-17. doi: 10.4103/ajm.AJM_70_17.
  19. Haji-Aghamohammadi AA, Bastani A, Miroliaee A, Oveisi S, Safarnezhad S. Comparison of levofloxacin versus clarithromycin efficacy in the eradication of Helicobacter pylori Caspian journal of internal medicine. 2016;7:267.
  20. Mohammed SA, Al-lela OQ, Hussein NR, Hajany RS, Alduhoky LS. Clarithromycin versus Levofloxacin-Based Regimens for Helicobacter Pylori Eradication in the Kurdistan Region of Iraq: A Randomized Clinical Trial. Gastroenterology Insights. 2019;10:5-9. org/10.4081/gi.2019.8256.
  21. Seyyedmajidi M, Abbasi L, Seyedmajidi S, Hosseini SA, Ahmadi A, Hajiebrahimi S, et al. Levofloxacin-containing triple therapy versus bismuth-based quadruple therapy as regimens for second line anti-Helicobacter pylori. Caspian journal of internal medicine. 2019;10:211. doi: 10.22088/cjim.10.2.211.
  22. Aksoy EK, Sapmaz FP, Göktaş Z, Uzman M, Nazlıgül Y. Comparison of helicobacter pylori eradication rates of 2-week levofloxacin-containing triple therapy, levofloxacin-containing bismuth quadruple therapy, and standard bismuth quadruple therapy as a first-line regimen. Medical Principles and Practice. 2017;26:523-9. doi: 10.1159/000484930.
  23. Itskoviz D, Boltin D, Leibovitzh H, Perets TT, Comaneshter D, Cohen A, Niv Y, Levi Z. Smoking increases the likelihood of Helicobacter pylori treatment failure. Digestive and Liver Disease. 2017;49:764-8. doi:10.1016/j.dld.2017.03.010.
  24. Cuadrado-Lavín A, Salcines-Caviedes JR, Carrascosa MF, Dierssen-Sotos T, Cobo M, Campos MR, et al. Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trial. Journal of Antimicrobial Chemotherapy. 2012;67:2254-9. org/10.1093/jac/dks209.
  25. Peedikayil MC, AlSohaibani FI, Alkhenizan AH. Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials. PLoS One. 2014;9: doi10.1371/journal.pone.0085620.
  26. Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016; 151:51-69 . e14. doi: 10.1053/j.gastro.2016.04.006.
Statistics
Article View: 317
PDF Download: 135


Journal Management System. Powered by iJournalPro.com